$IKT

Inhibikase Therapeutics, Inc.

CIK:0001750149|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Costs and expenses:
Research and development	$ 13,393,464	$ 5,270,967	$ 24,232,614	$ 15,784,546
Selling, general and administrative	7,657,531	5,919,731	15,033,654	11,169,022
Change in fair value	0	(358,420)	(373,354)	(1,523,284)
Total costs and expenses	21,050,995	10,832,278	38,892,914	25,430,284
Loss from operations	(21,050,995)	(10,832,278)	(38,892,914)	(25,430,284)
Other Income	1,459,764	916,755	2,920,843	1,836,026
Net loss	(19,591,231)	(9,915,523)	(35,972,071)	(23,594,258)
Unrealized gain (loss) on marketable securities	(46,461)	(1,977)	(94,556)	34,304
Comprehensive loss	$ (19,637,692)	$ (9,917,500)	$ (36,066,627)	$ (23,559,954)
Net loss per share - basic	$ (0.11)	$ (0.11)	$ (0.21)	$ (0.26)
Net loss per share - diluted	$ (0.11)	$ (0.11)	$ (0.21)	$ (0.26)
Weighted-average number of shares_ basic	174,571,543	90,009,625	173,445,493	89,774,703
Weighted-average number of shares_ diluted	174,571,543	90,009,625	173,445,493	89,774,703

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net Income (Loss)	$ (35,972,071)	$ (23,594,258)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	0	36,812
Stock-based compensation expense	10,905,776	6,250,938
Write-off of in-process research and development	0	7,357,294
Change in fair value	(373,354)	(1,523,284)
Non-cash accretion on marketable securities	(1,969,587)	0
Changes in operating assets and liabilities:
Operating lease right-of-use assets	0	66,519
Prepaid expenses and other current assets	(590,564)	7,526
Prepaid research and development	(1,344,648)	(57,547)
Other assets	(149,576)	0
Accounts payable	(196,334)	1,592,656
Operating lease liabilities	0	(72,573)
Accrued expenses and other current liabilities	5,187,024	258,156
Net cash used in operating activities	(24,503,334)	(9,677,761)
Cash flows from investing activities
Purchases of equipment and improvements	0	(13,399)
Purchases of investments - marketable securities	(145,618,289)	0
Maturities of investments - marketable securities	59,225,000	31,350,103
Acquired in-process research and development	0	(438,624)
Net cash provided by (used in) investing activities	(86,393,289)	30,898,080
Cash flows from financing activities
Deferred offering costs	(14,489)	0
Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs	2,897,611	150
Issuance of common stock from exercise of stock options	0	31,621
Net cash provided by financing activities	2,883,122	31,771
Net increase (decrease) in cash and cash equivalents	(108,013,501)	21,252,090
Cash and cash equivalents at beginning of period	139,220,208	56,490,579
Cash and cash equivalents at end of period	31,206,707	77,742,669
Supplemental disclosures of cash flow information
Issuance costs	85,000	0
Non cash investing and financing activities
Contingent consideration	0	2,912,159
Settlement of contingent consideration liability	2,688,147	0
Non-cash financing costs included in accounts payable and accrued expenses	30,000	307,373
CorHepta transaction costs	$ 0	$ 175,000

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 31,206,707	$ 139,220,208
Marketable securities	127,812,140	39,543,820
Prepaid research and development	2,346,641	1,001,993
Prepaid expenses and other current assets	933,938	343,374
Deferred offering costs	44,489	0
Total current assets	162,343,915	180,109,395
Prepaid research and development, noncurrent	1,000,000	1,000,000
Other assets	244,697	95,121
Total assets	163,588,612	181,204,516
Current liabilities:
Accounts payable	991,720	1,158,054
Accrued expenses and other current liabilities	9,268,306	4,081,282
Contingent consideration liability	0	3,061,501
Total current liabilities	10,260,026	8,300,837
Total liabilities	10,260,026	8,300,837
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025	0	0
Common stock, $0.001 par value; 500,000,000 shares authorized; 132,032,636 and 131,691,237 shares issued and outstanding (including 0 and 4,149,252 contingently issuable shares - see Note 10) at June 30, 2026 and December 31, 2025, respectively	132,032	131,691
Additional paid-in capital	331,921,179	315,429,986
Accumulated other comprehensive income (loss)	(72,754)	21,802
Accumulated deficit	(178,651,871)	(142,679,800)
Total stockholders' equity	153,328,586	172,903,679
Total liabilities and stockholders' equity	$ 163,588,612	$ 181,204,516